Skip to content
Menu

CorMedix Inc. CRMD

Full chart Compare
Set alert

Price alert · CRMD

All alert types
5.27 USD +0.19 (+3.74%)

Regular-session close

5.32 +0.05 +0.95%

After hours · Nov 20, 7:29 PM ET

4.95 Day range 5.32
4.50 52-week range 12.73
YTD
-54.69%
1 year
-45.78%

Fundamental scorecard

16 of 25 checks passed on CRMD’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 4 of 5
  • Growth 3 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 4 of 5

  • No data:P/E below its own 5-year median P/E 6.6. Not enough data to decide.
  • Passed:P/E under 20 P/E 6.6: an earnings yield of 15.2%.
  • Passed:Price to sales below its own 5-year median Price to sales 1.0 against a 5-year median of 459.
  • Passed:Price to book below its own 5-year median Price to book 0.9 against a 5-year median of 2.9.
  • Passed:Free cash flow yield above 4% Free cash flow of 308M is 73.4% of the market value.

Growth 3 of 5

  • Passed:Revenue grew over the last year Revenue of 412M is +92.5% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +319.7% a year from FY 2020 to FY 2025.
  • Failed:Earnings per share grew over the last year EPS 0.60 against 2.08 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years EPS -0.77 in FY 2020, 2.04 in FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 4 of 5

  • Passed:Profitable over the last year Net income of 63.9M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 1 of the last 5 fiscal years.
  • Passed:Return on equity above 15% Return on equity of 15.3%.
  • Passed:Net margin above its 5-year average Net margin of 15.5% against a 5-year average of -15043.4%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 308M is 481.9% of net income.

Financial health 5 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 503M against short-term liabilities of 207M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 503M against long-term liabilities of 249M.
  • Passed:Net debt under 40% of equity More cash than debt: 355M of cash against 145M of debt.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 313M is 215.1% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 75.0 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What CRMD owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 918M of assets

Debt, equity and cash by year

Now: 210M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

1.65 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

5 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B+3 / 5 overall

  • DCF 1
  • Return on Equity 4
  • Return on Assets 5
  • Debt / Equity 2
  • P/E 3
  • P/B 4

Valuation

P/E 5.2×
P/S 2.7×
P/B 2.1×
P/FCF 4.8×
EV/EBITDA 5.0×
EV/Sales 2.7×
FCF Yield 20.6%

Profitability

Gross Margin 88.5%
Operating Margin 48.2%
Net Margin 52.3%
ROE 40.2%
ROIC 23.0%
ROA 19.7%

Growth (YoY)

Revenue 617.0%
Operating Income 771.6%
EPS (diluted) 780.0%
Free Cash Flow 440.6%

Financial Health

Current Ratio 2.1×
Quick Ratio 1.9×
Debt / Equity 0.4×
Net Debt / EBITDA 0.0×
Interest Coverage 54.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31